Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Paulex Bio Inc.

Clinicaltrial registered28 Oct 2026

Paulex Bio Inc.

28 Oct 2026: Trial registered · Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
28 Oct 2026
Title
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes
Conditions
Healthy Volunteers and Diabetes Participants
Phase
Phase 1, Phase 2
Study Type
Interventional
Status
Not Yet Recruiting
Reference
NCT07901595
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Paulex Bio Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.